References
Harding JJ, Barker CA, Carvajal RD et al (2014) Cutis verticis gyrata in association with vemurafenib and whole-brain radiotherapy. J Clin Oncol 32:e54–56
Boussemart L, Routier E, Mateus C et al (2013) Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: a study of 42 patients. Ann Oncol 24:1691–1697
Schulze B, Meissner M, Wolter M et al (2014) Unusual acute and delayed skin reactions during and after whole-brain radiotherapy in combination with the BRAF inhibitor vemurafenib. Strahlenther Onkol 190:229–232
Rompoti N, Schilling B, Livingstone E et al (2013) Combination of BRAF inhibitors and brain radiotherapy in patients with metastatic melanoma shows minimal acute toxicity. J Clin Oncol 31:3844–3845
Compliance with ethical guidelines
Informed consent
Additional informed consent was obtained from all individual participants for whom identifying information is included in this article.
Conflict of interest
N. Lang, F. Sterzing, A. H. Enk, and J. C. Hassel state that there are no conflicts of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lang, N., Sterzing, F., Enk, A. et al. Cutis verticis gyrata-like skin toxicity during treatment of melanoma patients with the BRAF inhibitor vemurafenib after whole-brain radiotherapy is a consequence of the development of multiple follicular cysts and milia. Strahlenther Onkol 190, 1080–1081 (2014). https://doi.org/10.1007/s00066-014-0707-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00066-014-0707-0